Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCG142 in Advanced HPV-Associated Carcinomas
NCT06544720Phase 1Recruiting
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Aug 2023
- Primary completion
- Dec 2025
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SCG142 in Cervical Cancer (CC), head and neck cancer (HNC), anal cancer and 3 more, sponsored by The Affiliated Hospital of Qingdao University. Primary endpoint: Dose Limiting Toxicity at 28 days. Started Aug 2023; status: recruiting.
02
Drugs
SCG142
03
Conditions
Cervical Cancer (CC)head and neck cancer (HNC)anal cancervulvar cancervaginal cancer
Beyond the preview
Go deeper on NCT06544720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06544720.